Premium
Impact of previous hepatitis B infection on the clinical outcomes from chronic hepatitis C? A population‐level analysis
Author(s) -
Wang H.,
Swann R.,
Thomas E.,
Innes H. A.,
Valerio H.,
Hayes P. C.,
Allen S.,
Barclay S. T.,
Wilks D.,
Fox R.,
Bhattacharyya D.,
Kennedy N.,
Morris J.,
Fraser A.,
Stanley A. J.,
Gunson R.,
Mclntyre P. G.,
Hunt A.,
Hutchinson S. J.,
Mills P. R.,
Dillon J. F.
Publication year - 2018
Publication title -
journal of viral hepatitis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.329
H-Index - 100
eISSN - 1365-2893
pISSN - 1352-0504
DOI - 10.1111/jvh.12897
Subject(s) - medicine , hepatocellular carcinoma , cirrhosis , coinfection , hepatitis b virus , hazard ratio , hepatitis b , gastroenterology , hepatology , liver disease , population , hepatitis c virus , hepatitis c , immunology , virus , confidence interval , environmental health
Summary Chronic coinfection with hepatitis C virus ( HCV ) and hepatitis B virus ( HBV ) is associated with adverse liver outcomes. The clinical impact of previous HBV infection on liver disease in HCV infection is unknown. We aimed at determining any association of previous HBV infection with liver outcomes using antibodies to the hepatitis B core antigen ( HB cAb) positivity as a marker of exposure. The Scottish Hepatitis C Clinical Database containing data for all patients attending HCV clinics in participating health boards was linked to the HBV diagnostic registry and mortality data from Information Services Division, Scotland. Survival analyses with competing risks were constructed for time from the first appointment to decompensated cirrhosis, hepatocellular carcinoma ( HCC ) and liver‐related mortality. Records of 8513 chronic HCV patients were included in the analyses (87 HB cAb positive and HBV surface antigen [ HB sAg] positive, 1577 HB cAb positive and HB sAg negative, and 6849 HB cAb negative). Multivariate cause‐specific proportional hazards models showed previous HBV infection ( HB cAb positive and HB sAg negative) significantly increased the risks of decompensated cirrhosis (hazard ratio [ HR ]: 1.29, 95% CI : 1.01‐1.65) and HCC ( HR : 1.64, 95% CI : 1.09‐2.49), but not liver‐related death ( HR : 1.02, 95% CI : 0.80‐1.30). This is the largest study to date showing an association between previous HBV infection and certain adverse liver outcomes in HCV infection. Our analyses add significantly to evidence which suggests that HBV infection adversely affects liver health despite apparent clearance. This has important implications for HBV vaccination policy and indications for prioritization of HCV therapy.